

# Mimics and Red Flags of Multiple Sclerosis

Tomas Uher



Springer

---

## Mimics and Red Flags of Multiple Sclerosis

---

Tomas Uher

# Mimics and Red Flags of Multiple Sclerosis

Tomas Uher  
Multiple Sclerosis Centre, Neurology  
and Centre of Clinical Neuroscience  
First Faculty of Medicine Charles University  
and General University Hospital in Prague  
Prague, Czech Republic

ISBN 978-3-031-98944-5      ISBN 978-3-031-98945-2 (eBook)  
<https://doi.org/10.1007/978-3-031-98945-2>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2025

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

*“Life is like riding a bicycle. To keep your balance, you must keep moving.” (A. Einstein)*

*I dedicate my work to my patients, colleagues, friends, my family, and all good people. I would also like to express my gratitude to Professor Andrew J. Solomon for his valuable suggestions and for writing the foreword.*

*This publication was supported by the institutional support of the hospital research RVO-VFN 64165; Czech Ministry of Education—project Cooperatio LF1, research area Neuroscience; and the project National Institute for Neurological Research (Programme EXCELES, ID project No LX22NPO5107)—funded by the European Union—Next Generation EU.*

*This book has been written entirely by the author. ChatGPT, an AI language model, was utilized solely for correcting English grammar. The content, concepts, and ideas presented in this book remain the original work of the author.*

*The figures were created with Zoner Photo Studio X.*

---

## Foreword

The clinical and radiological heterogeneity of multiple sclerosis (MS) is widely acknowledged, and an accessible, highly sensitive and specific biomarker for MS remains an unmet need in clinical practice. Consequently, accurate diagnosis of MS relies upon clinical acumen that requires a breadth of knowledge for its differential diagnosis. Although MS diagnostic criteria have evolved over the last 60 years, each has relied upon the concept of “no better explanation” as a key element: disorders that may mimic MS must be considered and ruled out in order to diagnose MS.

Advancement in knowledge, particularly over the last decade, has required changes in clinical approaches to MS differential diagnosis. There has been increased recognition of neuroinflammatory disorders that may present with syndromes typical of MS. Newly identified clinical, laboratory, and radiological findings increasingly aid differentiation of these and other disorders from MS. In tandem, data from an expanding spectrum of clinical and radiological presentations previously considered atypical or insufficient for diagnosis challenge the boundaries of MS diagnostic criteria. Importantly, in this context, recent data also increasingly suggest that MS misdiagnosis is prevalent and associated with unnecessary medical risk and morbidity. In some cohorts, misdiagnosis has been identified in approximately one in seven patients who carry a diagnosis of MS. In sum, these recent developments inform optimal and nuanced approaches to MS differential diagnosis that necessitate greater expertise than was required in the past.

*Mimics and Red Flags of Multiple Sclerosis* by Dr. Tomáš Uher is a new and essential resource that will help inform the clinical care of patients where diagnosis of MS is being considered. This impressive accomplishment systematically and thoughtfully tackles the often daunting breadth of MS differential diagnosis. Comprehensive yet easy to navigate, its practical organization allows readers to quickly find disorders of interest. Each entry is accompanied by an efficient description of key clinical, laboratory, and radiological findings to facilitate accurate diagnosis. These findings are further enriched by a differential diagnosis provided for each disorder. Enhanced figures helpfully highlight MRI features that point to specific diagnoses. Updated data surrounding disease epidemiology, pathobiology, prognosis, and treatment complement diagnostic considerations to further aid

clinical care. This exceptionally detailed and thoroughly cited compendium will serve as a principal reference for clinicians navigating MS differential diagnosis in practice for many years to come.

Professor and Interim Chair,  
Department of Neurological Sciences  
and Division Chief, Multiple Sclerosis  
The Larner College of Medicine  
at The University of Vermont  
Burlington, VT, USA

Andrew J. Solomon

---

## Preface

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) presenting with a wide spectrum of clinical and radiological phenotypes. In clinical practice, many patients with MS are initially misdiagnosed with other medical conditions (false-negative diagnosis). Furthermore, patients with various medical conditions are incorrectly diagnosed with MS (false-positive diagnosis). Additionally, in some patients, when an alternative diagnosis is suspected, neither a comprehensive assessment nor observing the disease course over time provides any clues for an alternative diagnosis to MS. The relatively high frequency of MS misdiagnosis is due to the challenging differential diagnosis, which is mainly caused by the following reasons:

- MS has no specific biomarkers, and the diagnosis is made when no other explanations are found for the patient's neurological manifestations (diagnosis per exclusionem).
- The spectrum of alternative diagnoses that mimic MS is very broad.
- MS mimics include several very rare diagnoses, which may be unknown to clinicians owing to their rarity. Diagnosing these conditions may require complex and detailed genetic or metabolic assessments that may not be routinely available.
- There is increasing pressure to diagnose MS early because early treatment initiation is associated with better disease outcomes. However, the growing number of patients seen in practice, decreasing consultation times, and the urgency to start immuno-modulatory treatment (DMT) as soon as possible may lead to limited time for observing the disease course and thorough evaluation by physicians, potentially increasing the risk of misdiagnosis.
- The MS patient population is heterogeneous, and it is possible that a proportion of patients with atypical phenotypes diagnosed with MS have yet undefined or undiscovered diseases. Advances in research may result in discoveries of new diagnoses in the future, like how anti-aquaporin-4 (AQP4) IgG was identified 20 years ago and anti-myelin oligodendrocyte glycoprotein (MOG) IgG approximately 10 years ago.
- Incorrect application of the McDonald diagnostic criteria for MS.
- Geographically variable awareness of MS manifestations among the public and healthcare professionals, along with a shortage of neurologists with adequate



training and limited access to diagnostic equipment in some low- and middle-income countries.

Misdiagnosis of MS is a significant issue because it is associated with potential serious consequences:

- **False-Negative Diagnosis:** This leads to either late initiation or non-initiation of immunomodulatory treatment, which is associated with poorer prognosis of MS.
- **Untargeted Treatment:** Misdiagnosis prevents targeted treatment of the underlying medical condition, which may lead to disease progression and worse disease outcomes (e.g., not using enzyme replacement therapy in Fabry disease or biotin supplementation in patients with biotinidase deficiency).
- **Missed Genetic Counseling:** Patients with unrecognized or late-diagnosed inherited genetic diseases may miss opportunities for genetic counseling, aiding in family planning or prenatal diagnosis.
- **Negative Impact of MS Treatments:** Some treatments used for MS in patients with alternative diagnoses may have serious adverse effects (e.g., alemtuzumab, dimethyl-fumarate, glatiramer-acetate, interferons, natalizumab or S1P inhibitors in neuromyelitis optica spectrum disorder [NMOSD]; interferons in Susac's syndrome; immunosuppressive drugs in infectious diseases; natalizumab causing progressive multi-focal leukoencephalopathy [PML]; or alemtuzumab triggering autoimmune diseases).
- **High Financial Burden:** MS treatments are associated with high medical costs [1–7].

Neurologists may not frequently encounter patients with MS who present with atypical clinical courses, imaging findings, or biochemical abnormalities. However, managing these patients—who may have suspected alternative diagnoses to MS—can be extremely time-consuming. This is due to the lack of treatment response and the need for comprehensive assessments to rule out a wide range of potential diagnoses, often resulting in negative findings.

Given the wide range of MS mimickers, it is intellectually challenging to consider all alternative diagnoses and choose a rational diagnostic algorithm that is supported by red flags, rather than resorting to an expensive “fishing expedition” of examining everything. To address these concerns, my goal was to investigate further the differential diagnosis of MS. This investigation resulted in the creation of the book, where I have summarized contemporary knowledge on the manifestations and diagnosis of the most important MS mimickers in a structured manner.

The main aim of this work is to provide an inspiration for alternative diagnoses of MS when managing difficult or atypical cases of patients with potential diagnosis of MS and related demyelinating disorders.

This book has some limitations:

- **Scope:** The field is vast; therefore, only essential information on the clinical and paraclinical features of various conditions is provided. For a more in-depth understanding of specific diagnoses, consulting specialized literature is recommended.
- **Illustrations:** Real magnetic resonance scans have been replaced with scan-cartoon hybrid illustrations to enhance clarity and educational value.
- **Author's Experience:** This work is not based on extensive personal experience with patients diagnosed with the full spectrum of rare MS mimickers. Some of the diagnoses included are known to the author solely from the literature.
- **Consequently,** this work may contain inaccuracies, particularly when presenting information from non-neurological specialties such as radiology, genetics, and biochemistry. I sincerely apologize for any potential errors and encourage readers to share their feedback ([tomas.uher@vfn.cz](mailto:tomas.uher@vfn.cz) or [tomauher@gmail.com](mailto:tomauher@gmail.com)).

Despite these limitations, I hope this work inspires clinicians to carefully consider differential diagnoses in complex cases and proves valuable in their clinical practice.

Prague, Czech Republic

Tomas Uher

---

## References

1. Correale J, Solomon AJ, Cohen JA, Banwell BL, Gracia F, Gyang TV, et al. Differential diagnosis of suspected multiple sclerosis: global health considerations. *Lancet Neurol.* 2024;23(10):1035–49.
2. Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. *Lancet Neurol.* 2023;22(8):750–68.
3. Zürrer WE, Cannon AE, Ilchenko D, Gaitán MI, Granberg T, Piehl F, et al. Misdiagnosis and underdiagnosis of multiple sclerosis: a systematic review and meta-analysis. *Mult Scler.* 2024;30(11–12):1409–22.
4. Uher T, Adzima A, Srpova B, Noskova L, Marechal B, Maceski AM, et al. Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences. *Mult Scler.* 2023;29(11–12):1437–51.
5. Hua LH, Solomon AJ, Tenenbaum S, Scalfari A, Rovira À, Rostasy K, et al. Differential diagnosis of suspected multiple sclerosis in pediatric and late-onset populations: a review. *JAMA Neurol.* 2024.
6. Miller TM. Differential diagnosis of myotonic disorders. *Muscle Nerve.* 2008;37(3):293–9.
7. Solomon AJ, Pettigrew R, Naismith RT, Chahin S, Krieger S, Weinshenker B. Challenges in multiple sclerosis diagnosis: misunderstanding and misapplication of the McDonald criteria. *Mult Scler.* 2021;27(2):250–8.

---

## Competing Interests

The author has no competing interests to declare that are relevant to the content of this manuscript.

---

# Contents

<b>1</b>	<b>Multiple Sclerosis (MS)</b>	<b>1</b>
1.1	Epidemiology	1
1.2	Etiology and Definition	1
1.3	Clinical Features	2
1.4	Disease Course	3
1.5	Brain Imaging	4
1.6	Spinal Cord Imaging	8
1.7	Blood Work	10
1.8	Examination of CSF	10
1.9	Kappa Free Light Chain	11
1.10	Fundoscopy	11
1.11	OCT	12
1.12	Electrophysiological Studies	12
1.13	Diagnosis of Relapsing-Remitting MS	14
1.14	Diagnosis of Radiologically Isolated Syndrome (RIS)	15
1.15	Diagnosis of Clinically Isolated Syndrome (CIS)	16
1.16	Diagnosis of Primary Progressive MS (PPMS)	17
1.17	The McDonald 2024 Diagnostic Criteria	17
1.18	Treatment	18
1.19	Prognosis	19
	References	19
<b>2</b>	<b>Autoimmune Demyelinating Diseases of Central Nervous System (CNS)</b>	<b>25</b>
2.1	Acute Disseminated Encephalomyelitis (ADEM)	25
2.1.1	Epidemiology	25
2.1.2	Etiology and Definition	25
2.1.3	Clinical Features	26
2.1.4	Disease Course	26
2.1.5	Brain Imaging	27
2.1.6	Spinal Cord Imaging	28
2.1.7	Blood Work	29
2.1.8	Examination of CSF	29
2.1.9	Electrophysiology	30

2.1.10	Diagnosis . . . . .	30
2.1.11	Differential Diagnosis . . . . .	30
2.1.12	Treatment and Prognosis . . . . .	30
2.2	Acute Hemorrhagic Leukoencephalitis (AHLE) . . . . .	31
2.2.1	Synonyms. . . . .	31
2.2.2	Epidemiology . . . . .	31
2.2.3	Etiology and Definition . . . . .	31
2.2.4	Clinical Features . . . . .	31
2.2.5	Brain and Spinal Cord Imaging . . . . .	31
2.2.6	Blood Work . . . . .	31
2.2.7	Examination of CSF. . . . .	31
2.2.8	Diagnosis . . . . .	32
2.2.9	Differential Diagnosis . . . . .	32
2.2.10	Treatment and Prognosis . . . . .	32
2.3	Autoimmune Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy . . . . .	33
2.3.1	Epidemiology . . . . .	33
2.3.2	Etiology and Definition . . . . .	33
2.3.3	Clinical Features . . . . .	33
2.3.4	Disease Course. . . . .	34
2.3.5	Brain Imaging . . . . .	34
2.3.6	Spinal Cord Imaging . . . . .	34
2.3.7	Blood Work . . . . .	35
2.3.8	Examination of CSF. . . . .	35
2.3.9	OCT . . . . .	36
2.3.10	Electrophysiology . . . . .	36
2.3.11	Diagnosis . . . . .	36
2.3.12	Differential Diagnosis . . . . .	36
2.3.13	Treatment and Prognosis . . . . .	37
2.4	Baló Concentric Sclerosis . . . . .	37
2.4.1	Epidemiology . . . . .	37
2.4.2	Etiology and Definition . . . . .	37
2.4.3	Clinical Features . . . . .	38
2.4.4	Disease Course. . . . .	38
2.4.5	Brain Imaging . . . . .	38
2.4.6	Spinal Cord Imaging . . . . .	39
2.4.7	Blood Work . . . . .	39
2.4.8	Examination of CSF. . . . .	40
2.4.9	Diagnosis . . . . .	40
2.4.10	Differential Diagnosis . . . . .	40
2.4.11	Treatment and Prognosis . . . . .	40
2.5	Combined Central and Peripheral Demyelination . . . . .	40
2.5.1	Synonyms. . . . .	40
2.5.2	Epidemiology . . . . .	41
2.5.3	Etiology and Definition . . . . .	41

2.5.4	Clinical Features . . . . .	41
2.5.5	Disease Course. . . . .	41
2.5.6	Brain Imaging . . . . .	42
2.5.7	Spinal Cord Imaging . . . . .	42
2.5.8	Blood Work . . . . .	42
2.5.9	Examination of CSF. . . . .	42
2.5.10	OCT . . . . .	42
2.5.11	Electrophysiology . . . . .	42
2.5.12	Diagnosis . . . . .	42
2.5.13	Differential Diagnosis . . . . .	43
2.5.14	Treatment and Prognosis . . . . .	43
2.6	Idiopathic Acute Transverse Myelitis . . . . .	43
2.6.1	Epidemiology. . . . .	43
2.6.2	Etiology and Definition . . . . .	43
2.6.3	Clinical Features . . . . .	44
2.6.4	Brain Imaging . . . . .	44
2.6.5	Spinal Cord Imaging . . . . .	44
2.6.6	Blood Work . . . . .	45
2.6.7	Examination of CSF. . . . .	45
2.6.8	Diagnosis . . . . .	46
2.6.9	Differential Diagnosis . . . . .	46
2.6.10	Treatment and Prognosis . . . . .	46
2.7	Marburg's Variant of Multiple Sclerosis . . . . .	47
2.7.1	Epidemiology. . . . .	47
2.7.2	Etiology and Definition . . . . .	47
2.7.3	Clinical Features . . . . .	47
2.7.4	Disease Course. . . . .	47
2.7.5	Brain Imaging . . . . .	47
2.7.6	Spinal Cord Imaging . . . . .	48
2.7.7	Blood Work . . . . .	48
2.7.8	Examination of CSF. . . . .	48
2.7.9	Diagnosis . . . . .	48
2.7.10	Treatment and Prognosis . . . . .	48
2.8	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) . . . . .	48
2.8.1	Epidemiology. . . . .	48
2.8.2	Etiology and Definition . . . . .	49
2.8.3	Disease Course. . . . .	49
2.8.4	Optic Neuritis (Clinical and Imaging Features). . . . .	49
2.8.5	Transverse Myelitis (Clinical and Imaging Features) . . . . .	51
2.8.6	ADEM (Clinical and Imaging Features) . . . . .	52
2.8.7	Cerebral Cortical Encephalitis . . . . .	53
2.8.8	Brain Parenchymal Manifestations . . . . .	53
2.8.9	Blood Work . . . . .	55
2.8.10	Examination of CSF. . . . .	57

2.8.11	OCT . . . . .	57
2.8.12	Electrophysiology . . . . .	58
2.8.13	Diagnosis . . . . .	58
2.8.14	Differential Diagnosis . . . . .	58
2.8.15	Treatment and Prognosis . . . . .	59
2.9	Neuromyelitis Optica Spectrum Disorders (NMOSD) . . . . .	59
2.9.1	Synonyms. . . . .	59
2.9.2	Definition . . . . .	59
2.9.3	Epidemiology . . . . .	59
2.9.4	Etiology . . . . .	60
2.9.5	Clinical Features . . . . .	60
2.9.6	Disease Course. . . . .	62
2.9.7	Optic Nerve Imaging . . . . .	62
2.9.8	Brain Imaging . . . . .	63
2.9.9	Spinal Cord Imaging . . . . .	64
2.9.10	Imaging Red Flags for NMOSD . . . . .	67
2.9.11	Blood Work . . . . .	67
2.9.12	Examination of CSF. . . . .	68
2.9.13	Laboratory Red Flags for NMOSD . . . . .	69
2.9.14	OCT . . . . .	69
2.9.15	Electrophysiological Studies . . . . .	69
2.9.16	Diagnosis . . . . .	69
2.9.17	Differential Diagnosis . . . . .	71
2.9.18	Treatment . . . . .	77
2.9.19	Prognosis . . . . .	78
2.10	Post- and Para-Infectious Myelitis and Optic Neuritis . . . . .	78
2.11	Schilder's Disease . . . . .	78
2.11.1	Synonym . . . . .	78
2.11.2	Epidemiology . . . . .	78
2.11.3	Etiology and Definition . . . . .	78
2.11.4	Clinical Features . . . . .	79
2.11.5	Disease Course. . . . .	79
2.11.6	Brain Imaging . . . . .	79
2.11.7	Spinal Cord Imaging . . . . .	79
2.11.8	Blood Work . . . . .	80
2.11.9	Examination of CSF. . . . .	80
2.11.10	Diagnosis . . . . .	80
2.11.11	Differential Diagnosis . . . . .	80
2.11.12	Treatment and Prognosis . . . . .	81
2.12	Solitary Sclerosis . . . . .	81
2.12.1	Epidemiology . . . . .	81
2.12.2	Etiology and Definition . . . . .	81
2.12.3	Clinical Features . . . . .	81
2.12.4	Disease Course. . . . .	81
2.12.5	Brain and Spinal Cord Imaging . . . . .	82

2.12.6	Blood Work . . . . .	82
2.12.7	Examination of CSF. . . . .	83
2.12.8	Electrophysiology . . . . .	83
2.12.9	Diagnosis . . . . .	83
2.12.10	Differential Diagnosis . . . . .	83
2.12.11	Treatment and Prognosis . . . . .	83
2.13	Tumefactive Multiple Sclerosis . . . . .	84
2.13.1	Epidemiology . . . . .	84
2.13.2	Etiology and Definition . . . . .	84
2.13.3	Clinical Features . . . . .	84
2.13.4	Brain Imaging . . . . .	84
2.13.5	Spinal Cord Imaging . . . . .	85
2.13.6	Examination of CSF. . . . .	86
2.13.7	Diagnosis . . . . .	86
2.13.8	Differential Diagnosis . . . . .	87
2.13.9	Treatment and Prognosis . . . . .	87
	References. . . . .	87
<b>3</b>	<b>Autoimmune Non-demyelinating Diseases of Nervous System. . . . .</b>	<b>99</b>
3.1	Atopic Myelitis . . . . .	99
3.1.1	Synonym . . . . .	99
3.1.2	Epidemiology. . . . .	99
3.1.3	Etiology and Definition . . . . .	99
3.1.4	Clinical Features . . . . .	100
3.1.5	Disease Course. . . . .	100
3.1.6	Brain Imaging . . . . .	100
3.1.7	Spinal Cord Imaging . . . . .	100
3.1.8	Blood Work . . . . .	101
3.1.9	Examination of CSF. . . . .	102
3.1.10	Diagnosis . . . . .	102
3.1.11	Differential Diagnosis . . . . .	102
3.1.12	Treatment and Prognosis . . . . .	102
3.2	Autoimmune Encephalitis with Antibodies Against Neuronal Surface . . . . .	103
3.2.1	Epidemiology. . . . .	103
3.2.2	Etiology and Definition . . . . .	103
3.2.3	Clinical Features . . . . .	103
3.2.4	Disease Course. . . . .	104
3.2.5	Brain and Spinal Cord Imaging . . . . .	105
3.2.6	Blood Work . . . . .	106
3.2.7	Examination of CSF. . . . .	107
3.2.8	Biopsy . . . . .	108
3.2.9	Diagnosis . . . . .	108
3.2.10	Differential Diagnosis . . . . .	108
3.2.11	Treatment and Prognosis . . . . .	109



3.3	Bickerstaff's Brainstem Encephalitis. . . . .	109
3.3.1	Epidemiology . . . . .	109
3.3.2	Etiology and Definition . . . . .	109
3.3.3	Clinical Features . . . . .	110
3.3.4	Disease Course. . . . .	110
3.3.5	Brain Imaging . . . . .	111
3.3.6	Spinal Cord Imaging . . . . .	111
3.3.7	Blood Work . . . . .	112
3.3.8	Examination of CSF. . . . .	112
3.3.9	Electrophysiology . . . . .	112
3.3.10	Diagnosis . . . . .	112
3.3.11	Differential Diagnosis . . . . .	112
3.3.12	Treatment and Prognosis . . . . .	113
3.4	Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS) . . . . .	113
3.4.1	Epidemiology. . . . .	113
3.4.2	Etiology and Definition . . . . .	113
3.4.3	Clinical Features . . . . .	113
3.4.4	Disease Course. . . . .	114
3.4.5	Brain Imaging . . . . .	114
3.4.6	Spinal Cord Imaging . . . . .	115
3.4.7	Blood Work . . . . .	115
3.4.8	Examination of CSF. . . . .	115
3.4.9	Diagnosis . . . . .	116
3.4.10	Differential Diagnosis . . . . .	116
3.4.11	Treatment and Prognosis . . . . .	117
3.5	Hashimoto Encephalopathy . . . . .	117
3.6	Myasthenia Gravis . . . . .	118
3.6.1	Epidemiology. . . . .	118
3.6.2	Etiology and Definition . . . . .	118
3.6.3	Clinical Features . . . . .	118
3.6.4	Brain and Spinal Cord Imaging . . . . .	118
3.6.5	Blood Work . . . . .	118
3.6.6	Examination of CSF. . . . .	118
3.6.7	Electrophysiology . . . . .	119
3.6.8	Diagnosis . . . . .	119
3.6.9	Differential Diagnosis . . . . .	119
3.6.10	Treatment and Prognosis . . . . .	119
3.7	Primary Angiitis of the CNS (PACNS) . . . . .	119
3.7.1	Synonyms. . . . .	119
3.7.2	Epidemiology. . . . .	119
3.7.3	Etiology and Definition . . . . .	120
3.7.4	Clinical Features . . . . .	120
3.7.5	Disease Course. . . . .	120

3.7.6	Brain Imaging . . . . .	120
3.7.7	Spinal Cord Imaging . . . . .	122
3.7.8	Clinico-radiological Phenotypes of the PACNS . . . . .	122
3.7.9	Blood Work . . . . .	123
3.7.10	Examination of CSF. . . . .	123
3.7.11	OCT and Ophthalmological Assessment . . . . .	124
3.7.12	Diagnosis . . . . .	124
3.7.13	Differential Diagnosis . . . . .	124
3.7.14	Treatment and Prognosis . . . . .	126
	References. . . . .	126
<b>4</b>	<b>Autoimmune and Inflammatory Multisystem Diseases. . . . .</b>	<b>131</b>
4.1	Anti-phospholipid Syndrome. . . . .	131
4.1.1	Epidemiology. . . . .	131
4.1.2	Etiology and Definition . . . . .	131
4.1.3	Subtypes. . . . .	131
4.1.4	Non-neurological Clinical Features. . . . .	132
4.1.5	Neurological Clinical Features . . . . .	132
4.1.6	Ocular Features . . . . .	133
4.1.7	Brain Imaging . . . . .	133
4.1.8	Spinal Cord Imaging . . . . .	134
4.1.9	Blood Work . . . . .	135
4.1.10	Examination of CSF. . . . .	135
4.1.11	Electrophysiology . . . . .	135
4.1.12	Diagnosis . . . . .	135
4.1.13	Differential Diagnosis . . . . .	136
4.1.14	Treatment and Prognosis . . . . .	137
4.2	Behçet's Disease . . . . .	137
4.2.1	Epidemiology. . . . .	137
4.2.2	Etiology and Definition . . . . .	138
4.2.3	Non-neurological Clinical Features. . . . .	138
4.2.4	Neurological Clinical Features . . . . .	138
4.2.5	Disease Course. . . . .	140
4.2.6	Brain Imaging . . . . .	140
4.2.7	Spinal Cord Imaging . . . . .	141
4.2.8	Blood Work . . . . .	141
4.2.9	Examination of CSF. . . . .	142
4.2.10	OCT . . . . .	143
4.2.11	Electrophysiology . . . . .	143
4.2.12	Diagnosis . . . . .	143
4.2.13	Differential Diagnosis . . . . .	143
4.2.14	Treatment and Prognosis . . . . .	144
4.3	Celiac Disease . . . . .	144
4.3.1	Epidemiology. . . . .	144

4.3.2	Etiology and Definition . . . . .	144
4.3.3	Non-neurological Clinical Features . . . . .	144
4.3.4	Neurological Clinical Features . . . . .	145
4.3.5	Brain Imaging . . . . .	145
4.3.6	Spinal Cord Imaging . . . . .	145
4.3.7	Blood Work . . . . .	145
4.3.8	Examination of CSF. . . . .	146
4.3.9	Electrophysiology . . . . .	146
4.3.10	Diagnosis . . . . .	146
4.3.11	Differential Diagnosis . . . . .	147
4.3.12	Treatment and Prognosis . . . . .	147
4.4	Churg–Strauss Syndrome. . . . .	147
4.4.1	Synonyms. . . . .	147
4.4.2	Epidemiology. . . . .	147
4.4.3	Etiology and Definition . . . . .	147
4.4.4	Clinical Features . . . . .	148
4.4.5	Brain Imaging . . . . .	149
4.4.6	Spinal Cord Imaging . . . . .	149
4.4.7	Blood Work . . . . .	150
4.4.8	Examination of CSF. . . . .	150
4.4.9	Diagnosis . . . . .	150
4.4.10	Differential Diagnosis . . . . .	150
4.4.11	Treatment and Prognosis . . . . .	150
4.5	Cogan’s Syndrome. . . . .	151
4.5.1	Epidemiology. . . . .	151
4.5.2	Etiology and Definition . . . . .	151
4.5.3	Clinical Features . . . . .	151
4.5.4	Disease Course. . . . .	152
4.5.5	Brain Imaging . . . . .	152
4.5.6	Spinal Cord Imaging . . . . .	152
4.5.7	Blood Work . . . . .	152
4.5.8	Examination of CSF. . . . .	152
4.5.9	Diagnosis . . . . .	153
4.5.10	Differential Diagnosis . . . . .	153
4.5.11	Treatment and Prognosis . . . . .	153
4.6	Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) Haploinsufficiency . . . . .	154
4.6.1	Epidemiology. . . . .	154
4.6.2	Etiology and Definition . . . . .	154
4.6.3	Non-neurological Features. . . . .	154
4.6.4	Neurological Features . . . . .	154
4.6.5	Disease Course. . . . .	155
4.6.6	Brain Imaging . . . . .	155
4.6.7	Spinal Cord Imaging . . . . .	155
4.6.8	Blood Work . . . . .	155

4.6.9	Examination of CSF. . . . .	156
4.6.10	Diagnosis . . . . .	156
4.6.11	Treatment and Prognosis . . . . .	156
4.7	IgG4-Related Disease . . . . .	157
4.7.1	Epidemiology . . . . .	157
4.7.2	Etiology and Definition . . . . .	157
4.7.3	Non-neurological Features. . . . .	157
4.7.4	Neurological Features . . . . .	157
4.7.5	Disease Course. . . . .	158
4.7.6	Brain and Spinal Cord Imaging . . . . .	159
4.7.7	Blood Work . . . . .	159
4.7.8	Examination of CSF. . . . .	159
4.7.9	Diagnosis . . . . .	159
4.7.10	Differential Diagnosis . . . . .	160
4.7.11	Treatment and Prognosis . . . . .	160
4.8	Inflammatory Bowel Disease. . . . .	160
4.8.1	Epidemiology. . . . .	160
4.8.2	Etiology and Definition . . . . .	160
4.8.3	Intestinal Features . . . . .	161
4.8.4	Extraintestinal Non-neurological Features . . . . .	161
4.8.5	Neurological Features . . . . .	161
4.8.6	Brain Imaging . . . . .	161
4.8.7	Spinal Cord Imaging . . . . .	162
4.8.8	Examination of Blood and CSF. . . . .	162
4.8.9	Diagnosis . . . . .	162
4.8.10	Differential Diagnosis . . . . .	163
4.8.11	Treatment . . . . .	163
4.9	Rheumatoid Arthritis . . . . .	163
4.9.1	Epidemiology. . . . .	163
4.9.2	Etiology and Definition . . . . .	163
4.9.3	Joint and Systemic Features. . . . .	164
4.9.4	Neurological and Imaging Features Related to RA. . . . .	164
4.9.5	Neurological and Imaging Features Unrelated to RA . . . . .	165
4.9.6	Neurological and Imaging Features Related to Anti-TNF Drugs. . . . .	165
4.9.7	Blood Work . . . . .	166
4.9.8	Examination of CSF. . . . .	166
4.9.9	Diagnosis . . . . .	166
4.9.10	Treatment and Prognosis . . . . .	166
4.10	Sarcoidosis . . . . .	167
4.10.1	Epidemiology. . . . .	167
4.10.2	Etiology and Definition . . . . .	167
4.10.3	Non-neurological Clinical Features. . . . .	167
4.10.4	Cranial Neuropathy . . . . .	168
4.10.5	Aseptic Meningitis. . . . .	169

4.10.6	Hypothalamic/Pituitary Infiltration . . . . .	170
4.10.7	Brain Parenchymal Lesions . . . . .	170
4.10.8	Encephalopathy . . . . .	171
4.10.9	Vascular Disease . . . . .	171
4.10.10	Myelopathy . . . . .	171
4.10.11	Peripheral Involvement . . . . .	172
4.10.12	Disease Course. . . . .	174
4.10.13	Blood Work . . . . .	174
4.10.14	Examination of CSF. . . . .	174
4.10.15	Diagnosis . . . . .	175
4.10.16	Differential Diagnosis . . . . .	175
4.10.17	Treatment and Prognosis . . . . .	176
4.11	Sjogren's Syndrome. . . . .	176
4.11.1	Synonyms. . . . .	176
4.11.2	Epidemiology. . . . .	176
4.11.3	Etiology and Definition . . . . .	177
4.11.4	Subtypes. . . . .	177
4.11.5	Glandular Features. . . . .	177
4.11.6	Extra-glandular Systemic Features . . . . .	178
4.11.7	Neurological Features . . . . .	178
4.11.8	Disease Course of Neurological Manifestations . . . . .	180
4.11.9	Brain Imaging . . . . .	180
4.11.10	Spinal Cord Imaging . . . . .	180
4.11.11	Ultrasonography. . . . .	180
4.11.12	Blood Work . . . . .	180
4.11.13	Examination of CSF. . . . .	181
4.11.14	OCT . . . . .	181
4.11.15	Electrophysiology . . . . .	182
4.11.16	Diagnosis . . . . .	182
4.11.17	Differential Diagnosis . . . . .	183
4.11.18	Treatment. . . . .	184
4.11.19	Prognosis . . . . .	184
4.12	Susac's Syndrome . . . . .	185
4.12.1	Synonyms. . . . .	185
4.12.2	Epidemiology. . . . .	185
4.12.3	Etiology and Definition . . . . .	185
4.12.4	Clinical Features . . . . .	185
4.12.5	Disease Course. . . . .	187
4.12.6	Brain Imaging . . . . .	187
4.12.7	Spinal Cord Imaging . . . . .	188
4.12.8	Blood Work . . . . .	189
4.12.9	Examination of CSF. . . . .	189
4.12.10	OCT . . . . .	189
4.12.11	Histology . . . . .	189

4.12.12	Diagnosis . . . . .	189
4.12.13	Differential Diagnosis . . . . .	190
4.12.14	Treatment and Prognosis . . . . .	191
4.13	Systemic Lupus Erythematosus (SLE) . . . . .	191
4.13.1	Epidemiology . . . . .	191
4.13.2	Etiology and Definition . . . . .	192
4.13.3	Non-neurological Systemic Features . . . . .	192
4.13.4	Neurological Features . . . . .	192
4.13.5	Disease Course. . . . .	194
4.13.6	Brain Imaging . . . . .	194
4.13.7	Spinal Cord Imaging . . . . .	195
4.13.8	Blood Work . . . . .	195
4.13.9	Examination of CSF. . . . .	195
4.13.10	Examination of Blood and CSF in Different Subtypes of Demyelinative NPSLE. . . . .	196
4.13.11	Diagnosis of SLE. . . . .	197
4.13.12	Diagnosis of NPSLE . . . . .	197
4.13.13	Differential Diagnosis . . . . .	198
4.13.14	Treatment. . . . .	199
4.13.15	Prognosis . . . . .	199
4.14	Other Autoimmune Multisystem Diseases. . . . .	199
4.14.1	Ankylosing Spondylitis . . . . .	199
4.14.2	Relapsing Polychondritis. . . . .	200
4.14.3	Sneddon's Syndrome . . . . .	200
4.14.4	Systemic Sclerosis and Localized Scleroderma. . . . .	201
	References. . . . .	201
<b>5</b>	<b>Infectious Diseases . . . . .</b>	<b>215</b>
5.1	Brain Abscess. . . . .	215
5.1.1	Epidemiology. . . . .	215
5.1.2	Etiology and Definition . . . . .	215
5.1.3	Clinical Features . . . . .	216
5.1.4	Brain Imaging . . . . .	216
5.1.5	Blood Work . . . . .	217
5.1.6	Examination of CSF. . . . .	217
5.1.7	Diagnosis . . . . .	218
5.1.8	Differential Diagnosis . . . . .	218
5.1.9	Treatment and Prognosis . . . . .	218
5.2	Brucellosis . . . . .	218
5.2.1	Synonyms. . . . .	218
5.2.2	Epidemiology. . . . .	218
5.2.3	Etiology and Definition . . . . .	219
5.2.4	Disease Course. . . . .	219
5.2.5	Systemic Clinical Features. . . . .	219
5.2.6	Neurological Features . . . . .	219

5.2.7	Brain Imaging . . . . .	220
5.2.8	Spinal Cord Imaging . . . . .	220
5.2.9	Blood Work . . . . .	220
5.2.10	Examination of CSF. . . . .	221
5.2.11	Diagnosis . . . . .	221
5.2.12	Differential Diagnosis . . . . .	221
5.2.13	Treatment and Prognosis . . . . .	221
5.3	COVID-19 . . . . .	222
5.3.1	Etiology and Definition . . . . .	222
5.3.2	Respiratory Disease . . . . .	222
5.3.3	Neurological Involvement . . . . .	222
5.3.4	Diagnosis . . . . .	223
5.3.5	Differential Diagnosis: . . . . .	223
5.3.6	Treatment and Prevention . . . . .	224
5.4	Epstein–Barr Virus (EBV) . . . . .	224
5.4.1	Etiology . . . . .	224
5.4.2	Non-neurological Features of Acute Infection. . . . .	224
5.4.3	Neurological Clinical, Imaging, and Laboratory Features . . . . .	224
5.4.4	Diagnosis . . . . .	225
5.4.5	Treatment . . . . .	226
5.5	Hepatitis C (HCV) . . . . .	226
5.5.1	Epidemiology . . . . .	226
5.5.2	Etiology . . . . .	226
5.5.3	Hepatic Clinical Features. . . . .	226
5.5.4	Extrahepatic Non-neurological Clinical Features . . . . .	227
5.5.5	Neurological Clinical Features and Imaging . . . . .	227
5.5.6	Blood Work . . . . .	229
5.5.7	Examination of CSF. . . . .	229
5.5.8	Diagnosis . . . . .	229
5.5.9	Treatment and Prognosis . . . . .	229
5.6	Herpes Simplex Virus (HSV) Infections . . . . .	229
5.6.1	Epidemiology . . . . .	229
5.6.2	Cause and Definition . . . . .	230
5.6.3	Clinical Features . . . . .	230
5.6.4	Brain Imaging in HSV Encephalitis . . . . .	230
5.6.5	Spinal Cord Imaging . . . . .	231
5.6.6	Blood Work . . . . .	231
5.6.7	Examination of CSF. . . . .	232
5.6.8	Diagnosis . . . . .	232
5.6.9	Differential Diagnosis . . . . .	232
5.6.10	Treatment and Prognosis . . . . .	232
5.7	Human Immunodeficiency Virus (HIV). . . . .	233
5.7.1	Epidemiology . . . . .	233
5.7.2	Etiology and Definition . . . . .	233
5.7.3	Clinical Features . . . . .	233

5.7.4	Brain Imaging . . . . .	235
5.7.5	Spinal Cord Imaging . . . . .	236
5.7.6	Blood Work . . . . .	236
5.7.7	Examination of CSF. . . . .	236
5.7.8	Electrophysiological Studies . . . . .	237
5.7.9	Diagnosis . . . . .	237
5.7.10	Differential Diagnosis . . . . .	237
5.7.11	Treatment and Prognosis . . . . .	237
5.8	Human T-Lymphotropic Virus Type I (HTLV-1) Myelopathy. . . . .	238
5.8.1	Synonyms. . . . .	238
5.8.2	Epidemiology. . . . .	238
5.8.3	Etiology and Definition . . . . .	238
5.8.4	Clinical Features . . . . .	238
5.8.5	Disease Course. . . . .	239
5.8.6	Brain Imaging . . . . .	239
5.8.7	Spinal Cord Imaging . . . . .	239
5.8.8	Examination of Blood and CSF. . . . .	240
5.8.9	Electrophysiology . . . . .	240
5.8.10	Diagnosis . . . . .	240
5.8.11	Differential Diagnosis . . . . .	241
5.8.12	Treatment and Prognosis . . . . .	241
5.9	Lyme Neuroborreliosis. . . . .	241
5.9.1	Etiology and Definition . . . . .	241
5.9.2	Epidemiology. . . . .	241
5.9.3	Stage 1 (Early Localized Lyme disease; After 1–4 Weeks from Infection) . . . . .	242
5.9.4	Stage 2 (Early Disseminated Lyme Disease; After Weeks to 4 Months from Infection) . . . . .	242
5.9.5	Stage 3 (Late disseminated Lyme Disease; After >4 Months from Infection) . . . . .	244
5.9.6	Brain Imaging . . . . .	245
5.9.7	Spinal Cord Imaging . . . . .	245
5.9.8	Blood Work . . . . .	245
5.9.9	Examination of CSF. . . . .	245
5.9.10	Electrophysiology . . . . .	247
5.9.11	Diagnosis . . . . .	247
5.9.12	Differential Diagnosis . . . . .	248
5.9.13	Treatment and Prognosis . . . . .	248
5.10	Progressive Multifocal Leukoencephalopathy (PML). . . . .	249
5.10.1	Epidemiology. . . . .	249
5.10.2	Etiology and Definition . . . . .	249
5.10.3	Clinical Features . . . . .	250
5.10.4	Brain Imaging . . . . .	251
5.10.5	PML Subtypes According to Brain MRI . . . . .	253
5.10.6	Spinal Cord Imaging . . . . .	253
5.10.7	Blood Work . . . . .	253



5.10.8	Examination of CSF. . . . .	254
5.10.9	Diagnosis . . . . .	254
5.10.10	Differential Diagnosis . . . . .	254
5.10.11	Treatment and Prognosis . . . . .	255
5.11	Syphilis . . . . .	255
5.11.1	Epidemiology . . . . .	255
5.11.2	Etiology and Definition . . . . .	256
5.11.3	Disease Course. . . . .	256
5.11.4	Asymptomatic Neurosyphilis. . . . .	256
5.11.5	Clinical Features of Early Neurosyphilis. . . . .	256
5.11.6	Clinical Features of Late Neurosyphilis . . . . .	257
5.11.7	Brain Imaging . . . . .	257
5.11.8	Spinal Cord Imaging . . . . .	258
5.11.9	Blood Work . . . . .	259
5.11.10	Examination of CSF. . . . .	260
5.11.11	Diagnosis . . . . .	261
5.11.12	Differential Diagnosis . . . . .	261
5.11.13	Treatment and Prognosis . . . . .	261
5.12	Tuberculosis. . . . .	262
5.12.1	Epidemiology. . . . .	262
5.12.2	Etiology and Definition . . . . .	262
5.12.3	Tuberculosis Subtypes . . . . .	262
5.12.4	Tuberculous Meningitis . . . . .	262
5.12.5	Brain Parenchymal Tuberculosis . . . . .	263
5.12.6	Spinal Cord Tuberculosis. . . . .	263
5.12.7	Blood Work . . . . .	264
5.12.8	Examination of CSF. . . . .	265
5.12.9	Diagnosis . . . . .	265
5.12.10	Treatment and Prognosis . . . . .	265
5.13	Varicella Zoster Virus (VZV) Infection . . . . .	266
5.13.1	Epidemiology. . . . .	266
5.13.2	Cause . . . . .	266
5.13.3	Clinical Features and Imaging . . . . .	266
5.13.4	Blood Work . . . . .	268
5.13.5	Examination of CSF. . . . .	269
5.13.6	Diagnosis . . . . .	269
5.13.7	Treatment and Prognosis . . . . .	270
5.14	Whipple Disease . . . . .	270
5.14.1	Epidemiology. . . . .	270
5.14.2	Etiology and Definition . . . . .	270
5.14.3	Systemic Clinical Features. . . . .	270
5.14.4	Neurological Clinical Features . . . . .	270
5.14.5	Disease Course. . . . .	271
5.14.6	Brain Imaging . . . . .	271
5.14.7	Spinal Cord Imaging . . . . .	272

5.14.8	Examination of CSF. . . . .	272
5.14.9	Diagnosis . . . . .	272
5.14.10	Differential Diagnosis . . . . .	272
5.14.11	Treatment and Prognosis . . . . .	272
5.15	Other Bacterial, Parasitic, and Fungal Infections . . . . .	273
5.15.1	Cat Scratch Disease . . . . .	273
5.15.2	Chagas Disease (American Trypanosomiasis). . . . .	274
5.15.3	Cryptococcal Meningitis . . . . .	275
5.15.4	Cysticercosis . . . . .	276
5.15.5	Leptospirosis . . . . .	276
5.15.6	Listeria Monocytogenes. . . . .	277
5.15.7	Mediterranean Spotted Fever . . . . .	279
5.15.8	Mycoplasma Pneumonia Infection . . . . .	279
5.15.9	Schistosomiasis . . . . .	281
5.15.10	Toxocarosis . . . . .	282
5.16	Other Viral Infections. . . . .	284
5.16.1	Acute Flaccid Myelitis. . . . .	284
5.16.2	Cytomegalovirus (CMV) Infection . . . . .	285
5.16.3	Dengue Fever. . . . .	286
5.16.4	Enterovirus 71 . . . . .	288
5.16.5	Hepatitis A (HAV) and B (HBV). . . . .	288
5.16.6	Hepatitis E (HEV) . . . . .	289
5.16.7	Human Herpesvirus 6 (HHV-6). . . . .	290
5.16.8	Human Parvovirus (B19V) . . . . .	291
5.16.9	Subacute Sclerosing Panencephalitis (SSPE) . . . . .	292
5.16.10	West Nile Virus . . . . .	293
	References. . . . .	295
<b>6</b>	<b>Acquired Metabolic and Nutritional Diseases . . . . .</b>	<b>311</b>
6.1	Central Pontine Myelinolysis. . . . .	311
6.1.1	Epidemiology. . . . .	311
6.1.2	Etiology and Definition . . . . .	311
6.1.3	Clinical Features . . . . .	312
6.1.4	Brain Imaging . . . . .	312
6.1.5	Spinal Cord Imaging . . . . .	313
6.1.6	Blood Work . . . . .	313
6.1.7	Examination of CSF. . . . .	313
6.1.8	Diagnosis . . . . .	313
6.1.9	Differential Diagnosis . . . . .	313
6.1.10	Treatment and Prognosis . . . . .	314
6.2	Cobalamin and Folate Deficiency . . . . .	314
6.2.1	Epidemiology. . . . .	314
6.2.2	Etiology . . . . .	314
6.2.3	Non-neurological Clinical Features. . . . .	314
6.2.4	Neurological Clinical Features . . . . .	315

6.2.5	Brain Imaging . . . . .	315
6.2.6	Spinal Cord Imaging . . . . .	315
6.2.7	Electrophysiology . . . . .	315
6.2.8	Blood Work . . . . .	316
6.2.9	Examination of CSF. . . . .	316
6.2.10	Diagnosis . . . . .	316
6.2.11	Treatment and Prognosis . . . . .	317
6.3	Cooper Deficiency and Zinc Overload. . . . .	317
6.3.1	Etiology . . . . .	317
6.3.2	Clinical Features . . . . .	317
6.3.3	Brain Imaging . . . . .	317
6.3.4	Spinal Cord Imaging . . . . .	317
6.3.5	Blood Work . . . . .	318
6.3.6	Examination of CSF. . . . .	318
6.3.7	Treatment and Prognosis . . . . .	318
6.4	Lathyrism. . . . .	318
6.5	Marchiafava–Bignami Disease . . . . .	318
6.5.1	Epidemiology. . . . .	318
6.5.2	Etiology and Definition . . . . .	319
6.5.3	Clinical Features . . . . .	319
6.5.4	Brain Imaging . . . . .	319
6.5.5	Spinal Cord Imaging . . . . .	320
6.5.6	Examination of Blood and CSF. . . . .	320
6.5.7	Diagnosis . . . . .	321
6.5.8	Differential Diagnosis . . . . .	321
6.5.9	Treatment and Prognosis . . . . .	321
6.6	Nitrous Oxide-Induced Myeloneuropathy . . . . .	321
6.6.1	Synonyms. . . . .	321
6.6.2	Epidemiology. . . . .	321
6.6.3	Etiology and Definition . . . . .	321
6.6.4	Clinical Features . . . . .	322
6.6.5	Brain Imaging . . . . .	322
6.6.6	Spinal Cord Imaging . . . . .	322
6.6.7	Blood Work . . . . .	322
6.6.8	Examination of CSF. . . . .	323
6.6.9	Electrophysiology . . . . .	323
6.6.10	Diagnosis . . . . .	323
6.6.11	Treatment and Prognosis . . . . .	323
6.7	Vitamin E Deficiency. . . . .	323
6.7.1	Etiology . . . . .	323
6.7.2	Clinical Features . . . . .	324
6.7.3	Disease Course. . . . .	325
6.7.4	Brain Imaging . . . . .	325
6.7.5	Spinal Cord Imaging . . . . .	325
6.7.6	Electrophysiology . . . . .	325

6.7.7	Blood Work . . . . .	325
6.7.8	Examination of CSF. . . . .	325
6.7.9	Diagnosis . . . . .	326
6.7.10	Treatment and Prognosis . . . . .	326
6.8	Wernicke Encephalopathy . . . . .	326
6.8.1	Epidemiology . . . . .	326
6.8.2	Etiology and Definition . . . . .	326
6.8.3	Clinical Features . . . . .	326
6.8.4	Brain Imaging . . . . .	327
6.8.5	Spinal Cord Imaging . . . . .	328
6.8.6	Blood Work . . . . .	328
6.8.7	Examination of CSF. . . . .	328
6.8.8	Diagnosis . . . . .	328
6.8.9	Differential Diagnosis . . . . .	329
6.8.10	Treatment and Prognosis . . . . .	329
	References. . . . .	329
<b>7</b>	<b>Inherited Metabolic Diseases . . . . .</b>	<b>333</b>
7.1	Biotinidase Deficiency . . . . .	333
7.1.1	Epidemiology. . . . .	333
7.1.2	Etiology and Definition . . . . .	333
7.1.3	Clinical Features . . . . .	333
7.1.4	Brain Imaging . . . . .	334
7.1.5	Spinal Cord Imaging . . . . .	334
7.1.6	Blood Work . . . . .	334
7.1.7	Urine Analysis . . . . .	335
7.1.8	Examination of CSF. . . . .	335
7.1.9	OCT . . . . .	335
7.1.10	Electrophysiological Studies . . . . .	336
7.1.11	Diagnosis . . . . .	336
7.1.12	Differential Diagnosis . . . . .	336
7.1.13	Treatment and Prognosis . . . . .	336
7.2	Cerebrotendinous Xanthomatosis . . . . .	336
7.2.1	Epidemiology. . . . .	336
7.2.2	Etiology and Definition . . . . .	337
7.2.3	Non-neurological Clinical Features. . . . .	337
7.2.4	Neurological Clinical Features . . . . .	338
7.2.5	Disease Course. . . . .	338
7.2.6	Brain Imaging . . . . .	338
7.2.7	Spinal Cord Imaging . . . . .	339
7.2.8	Blood Work . . . . .	339
7.2.9	Examination of CSF. . . . .	340
7.2.10	Electrophysiological Studies . . . . .	340
7.2.11	Diagnosis . . . . .	340
7.2.12	Differential Diagnosis . . . . .	341

7.2.13	Treatment and Prognosis . . . . .	341
7.3	Fabry Disease . . . . .	341
7.3.1	Epidemiology . . . . .	341
7.3.2	Etiology and Definition . . . . .	341
7.3.3	Subtypes . . . . .	342
7.3.4	Neurological Clinical Features . . . . .	342
7.3.5	Non-neurological Clinical Features . . . . .	342
7.3.6	Brain Imaging . . . . .	343
7.3.7	Spinal Cord Imaging . . . . .	343
7.3.8	Blood Work . . . . .	344
7.3.9	Examination of CSF . . . . .	344
7.3.10	Electrophysiology . . . . .	344
7.3.11	Diagnosis in Males . . . . .	344
7.3.12	Diagnosis in Females . . . . .	345
7.3.13	Differential Diagnosis . . . . .	345
7.3.14	Treatment and Prognosis . . . . .	346
7.4	Homocysteine Remethylation Disorders . . . . .	346
7.4.1	Etiology . . . . .	346
7.4.2	Clinical Features . . . . .	346
7.4.3	Brain Imaging . . . . .	347
7.4.4	Spinal Cord Imaging . . . . .	347
7.4.5	Electrophysiology . . . . .	347
7.4.6	Blood Work . . . . .	348
7.4.7	Examination of Urine . . . . .	348
7.4.8	Examination of CSF . . . . .	348
7.4.9	Diagnosis . . . . .	348
7.4.10	Treatment and Prognosis . . . . .	348
7.5	Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) Syndrome and Other Disorders of Glutamate and Urea Cycle Metabolism . . . . .	348
7.5.1	Epidemiology . . . . .	348
7.5.2	Etiology and Definition . . . . .	349
7.5.3	Clinical Features . . . . .	349
7.5.4	Disease Course . . . . .	349
7.5.5	Brain Imaging . . . . .	349
7.5.6	Spinal Cord Imaging . . . . .	350
7.5.7	Examination of Blood and CSF . . . . .	350
7.5.8	Electrophysiology . . . . .	350
7.5.9	Diagnosis . . . . .	351
7.5.10	Differential Diagnosis . . . . .	351
7.5.11	Treatment and Prognosis . . . . .	351
7.6	Lysosomal Storage and Peroxisomal Function Disorders . . . . .	351
7.6.1	Epidemiology . . . . .	351
7.6.2	Cause and Definition . . . . .	352
7.6.3	X-Linked Adrenoleukodystrophy (X-ALD) . . . . .	352

7.6.4	Krabbe Disease . . . . .	354
7.6.5	Metachromatic Leukodystrophy . . . . .	355
7.6.6	Fabry Disease . . . . .	356
7.6.7	Niemann–Pick Disease Type C . . . . .	357
7.6.8	Chédiak–Higashi Disease . . . . .	358
7.6.9	Tay-Sachs Disease . . . . .	359
7.6.10	Pompe Disease . . . . .	359
7.6.11	Blood Work (in General) . . . . .	360
7.6.12	Examination of CSF (in General) . . . . .	360
7.6.13	Diagnosis (in General) . . . . .	360
7.6.14	Treatment and Prognosis (in General) . . . . .	361
7.7	Mitochondrial Disorders . . . . .	361
7.7.1	Epidemiology . . . . .	361
7.7.2	Cause and Definition . . . . .	361
7.7.3	Subtypes . . . . .	361
7.7.4	Non-neurological Clinical Features . . . . .	362
7.7.5	Neurological Clinical and Imaging Features . . . . .	363
7.7.6	Disease Course . . . . .	364
7.7.7	Brain Imaging . . . . .	364
7.7.8	Spinal Cord Imaging . . . . .	366
7.7.9	Other Organ Systems Imaging . . . . .	366
7.7.10	Blood Work . . . . .	367
7.7.11	Examination of CSF . . . . .	368
7.7.12	OCT . . . . .	368
7.7.13	Electrophysiology . . . . .	368
7.7.14	Diagnosis . . . . .	368
7.7.15	Differential Diagnosis . . . . .	369
7.7.16	Treatment and Prognosis . . . . .	369
7.8	Wilson’s Disease . . . . .	369
7.8.1	Epidemiology . . . . .	369
7.8.2	Etiology . . . . .	369
7.8.3	Clinical Features . . . . .	369
7.8.4	Brain Imaging . . . . .	370
7.8.5	Spinal Cord Imaging . . . . .	370
7.8.6	Blood Work . . . . .	370
7.8.7	Urine . . . . .	371
7.8.8	Liver Biopsy . . . . .	371
7.8.9	Examination of CSF . . . . .	371
7.8.10	Treatment and Prognosis . . . . .	371
7.9	Other Rare Inherited Metabolic Diseases . . . . .	371
7.9.1	Acute Intermittent Porphyria . . . . .	371
7.9.2	Alpha-Methylacyl-CoA Racemase Deficiency . . . . .	371
7.9.3	Adult Polyglucosan Body Disease . . . . .	372
7.9.4	Aicardi–Goutières Syndrome . . . . .	372
7.9.5	Arginase I Deficiency . . . . .	373